Last Updated : March 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
---|---|---|---|---|---|---|
Palynziq | pegvaliase | Phenylketonuria | Reimburse with clinical criteria and/or conditions | Complete | ||
Vraylar | cariprazine | Bipolar Disorder | Do not reimburse | Complete | ||
Xydalba | dalbavancin | Acute bacterial skin and skin structure infections | Reimburse with clinical criteria and/or conditions | Complete | ||
Tezspire | tezepelumab | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
Nucala | mepolizumab | Severe chronic rhinosinusitis with nasal polyps | Reimburse with clinical criteria and/or conditions | Complete | ||
Tremfya | guselkumab | Psoriatic arthritis | Reimburse with clinical criteria and/or conditions | Complete | ||
Zeposia | ozanimod | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | recurrent, or metastatic cervical cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Wakix | pitolisant hydrochloride | Narcolepsy | Do not reimburse | Complete | ||
Ozurdex | dexamethasone intravitreal implant | Diabetic macular edema | Do not reimburse | Complete |